Paul G. Richardson

131.3k total citations · 18 hit papers
1.1k papers, 51.8k citations indexed

About

Paul G. Richardson is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Paul G. Richardson has authored 1.1k papers receiving a total of 51.8k indexed citations (citations by other indexed papers that have themselves been cited), including 944 papers in Hematology, 704 papers in Molecular Biology and 482 papers in Oncology. Recurrent topics in Paul G. Richardson's work include Multiple Myeloma Research and Treatments (885 papers), Protein Degradation and Inhibitors (410 papers) and Peptidase Inhibition and Analysis (263 papers). Paul G. Richardson is often cited by papers focused on Multiple Myeloma Research and Treatments (885 papers), Protein Degradation and Inhibitors (410 papers) and Peptidase Inhibition and Analysis (263 papers). Paul G. Richardson collaborates with scholars based in United States, Spain and France. Paul G. Richardson's co-authors include Kenneth C. Anderson, Teru Hideshima, Dharminder Chauhan, Constantine S. Mitsiades, Nikhil C. Munshi, Robert Schlossman, Noopur Raje, Klaus Podar, Nicholas Mitsiades and Jacob P. Laubach and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Paul G. Richardson

1.1k papers receiving 50.6k citations

Hit Papers

The proteasome inhibitor ... 2000 2026 2008 2017 2001 2002 2001 2000 2007 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
    2001 1.2k citations Teru Hideshima, Paul G. Richardson et al. PubMed profile →
  2. NF-κB as a Therapeutic Target in Multiple Myeloma
    2002 752 citations Teru Hideshima, Dharminder Chauhan et al. profile →
  3. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    2001 740 citations Noopur Raje, Teru Hideshima et al. Blood profile →
  4. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
    2000 708 citations Teru Hideshima, Dharminder Chauhan et al. Blood profile →
  5. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
    2007 702 citations Teru Hideshima, Constantine S. Mitsiades et al. profile →
  6. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    2002 630 citations Paul G. Richardson, Robert Schlossman et al. Blood profile →
  7. Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    2002 597 citations Nicholas Mitsiades, Dharminder Chauhan et al. profile →
  8. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    2003 575 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →
  9. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
    2004 569 citations Sundar Jagannath, David S. Siegel et al. profile →
  10. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    2005 560 citations Dharminder Chauhan, Teru Hideshima et al. profile →
  11. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    2002 544 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →
  12. Multiple myeloma
    2009 533 citations Paul G. Richardson, Kenneth C. Anderson et al. profile →
  13. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
    2017 392 citations Paul G. Richardson, Philippe Moreau et al. Journal of Clinical Oncology profile →
  14. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
    2014 375 citations Yu‐Tzu Tai, Chirag Acharya et al. Blood profile →
  15. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
    2018 364 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
  16. CD38 antibodies in multiple myeloma: back to the future
    2017 333 citations Paul G. Richardson et al. Blood profile →
  17. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    2016 303 citations Peter M. Voorhees, Paul G. Richardson et al. Blood profile →
  18. Extramedullary disease in multiple myeloma: a systematic literature review
    2022 111 citations Philippe Moreau, Paul G. Richardson et al. Blood Cancer Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul G. Richardson United States 116 33.9k 32.3k 22.5k 5.9k 4.6k 1.1k 51.8k
Nikhil C. Munshi United States 106 25.2k 0.7× 21.5k 0.7× 16.7k 0.7× 6.1k 1.0× 3.6k 0.8× 799 40.1k
Bart Barlogie United States 109 24.5k 0.7× 30.7k 0.9× 18.3k 0.8× 4.0k 0.7× 5.7k 1.2× 704 42.4k
S. Vincent Rajkumar United States 114 33.7k 1.0× 38.7k 1.2× 21.5k 1.0× 3.3k 0.6× 9.9k 2.1× 898 53.8k
Teru Hideshima United States 100 24.6k 0.7× 17.5k 0.5× 13.3k 0.6× 4.6k 0.8× 2.5k 0.5× 472 34.9k
Michael Andreeff United States 112 25.9k 0.8× 16.0k 0.5× 13.6k 0.6× 7.1k 1.2× 10.3k 2.2× 1.0k 48.1k
Shaji Kumar United States 89 22.8k 0.7× 23.4k 0.7× 14.0k 0.6× 2.7k 0.5× 5.7k 1.2× 1.0k 35.0k
Angela Dispenzieri United States 106 31.7k 0.9× 25.5k 0.8× 15.6k 0.7× 2.6k 0.4× 9.3k 2.0× 976 47.8k
Charles L. Sawyers United States 99 24.8k 0.7× 15.8k 0.5× 12.3k 0.5× 3.2k 0.5× 11.6k 2.5× 266 53.4k
Brian Druker United States 106 17.1k 0.5× 30.5k 0.9× 10.9k 0.5× 5.8k 1.0× 21.7k 4.7× 607 54.8k
Francis J. Giles United States 105 15.0k 0.4× 20.4k 0.6× 9.3k 0.4× 4.6k 0.8× 15.8k 3.4× 786 41.9k

Countries citing papers authored by Paul G. Richardson

Since Specialization
Citations

This map shows the geographic impact of Paul G. Richardson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul G. Richardson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul G. Richardson more than expected).

Fields of papers citing papers by Paul G. Richardson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul G. Richardson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul G. Richardson. The network helps show where Paul G. Richardson may publish in the future.

Co-authorship network of co-authors of Paul G. Richardson

This figure shows the co-authorship network connecting the top 25 collaborators of Paul G. Richardson. A scholar is included among the top collaborators of Paul G. Richardson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul G. Richardson. Paul G. Richardson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Richardson, Paul G., Aurore Perrot, Joseph Mıkhael, et al.. (2024). Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. Blood Cancer Journal. 14(1). 209–209. 3 indexed citations
2.
Gullà, Annamaria, Eugenio Morelli, Mehmet Samur, et al.. (2021). Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. Blood Cancer Discovery. 2(5). 468–483. 92 indexed citations
3.
Ghobrial, Irene M., Chia‐Jen Liu, Robert Redd, et al.. (2019). A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 26(2). 344–353. 79 indexed citations
4.
5.
Lin, Liang, Lijie Xing, Chirag Acharya, et al.. (2017). CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo. Blood. 130. 3067–3067. 6 indexed citations
6.
Odejide, Oreofe O., Ling Li, Angel M. Cronin, et al.. (2017). Hospice Use Among Patients with Myeloma. Blood. 130. 346–346. 1 indexed citations
7.
Siegel, David S., Katja Weisel, Meletios Α. Dimopoulos, et al.. (2016). Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leukemia & lymphoma. 57(12). 2833–2838. 21 indexed citations
8.
Tang, Min, Rui Zhao, Helgi van de Velde, et al.. (2016). Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clinical Cancer Research. 22(16). 4206–4214. 20 indexed citations
9.
Raje, Noopur, Edward A. Faber, Paul G. Richardson, et al.. (2016). Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 22(23). 5688–5695. 22 indexed citations
10.
Cottini, Francesca, Teru Hideshima, Rikio Suzuki, et al.. (2015). Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discovery. 5(9). 972–987. 87 indexed citations
11.
Mimura, Naoya, Teru Hideshima, Toshiyasu Shimomura, et al.. (2014). Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. Cancer Research. 74(16). 4458–4469. 66 indexed citations
12.
Fabre, Claire, Naoya Mimura, Kathryn Bobb, et al.. (2012). Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research. 18(17). 4669–4681. 66 indexed citations
13.
McMillin, Douglas W., Hannah M. Jacobs, Jake Delmore, et al.. (2012). Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. Molecular Cancer Therapeutics. 11(4). 942–951. 46 indexed citations
14.
Dimopoulos, Meletios Α., Paul G. Richardson, Nancy A. Brandenburg, et al.. (2012). A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 119(12). 2764–2767. 108 indexed citations
15.
Jakubı́ková, Jana, Sophia Adamia, Maria Kost‐Alimova, et al.. (2011). Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 117(17). 4409–4419. 122 indexed citations
16.
Ghobrial, Irene M., Morie A. Gertz, Betsy LaPlant, et al.. (2010). Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1408–1414. 102 indexed citations
17.
Mitsiades, Constantine S., Cécile Rouleau, Cinara Echart, et al.. (2009). Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias. Clinical Cancer Research. 15(4). 1210–1221. 46 indexed citations
18.
Ooi, Melissa, Patrick Hayden, Vassiliki Kotoula, et al.. (2009). Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research. 15(23). 7153–7160. 53 indexed citations
19.
McMillin, Douglas W., Melissa Ooi, Jake Delmore, et al.. (2009). Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Cancer Research. 69(14). 5835–5842. 105 indexed citations
20.
Richardson, Paul G., et al.. (1964). TREATMENT OF INFANTILE HEMANGIOMAS. ACTIVE INTERVENTION OR CONSERVATIVE MANAGEMENT OF STRAWBERRY NEVI?. PubMed. 64. 2076–81. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nikhil C. Munshi Breakdown of academic impact, for papers by Bart Barlogie Breakdown of academic impact, for papers by S. Vincent Rajkumar Breakdown of academic impact, for papers by Teru Hideshima Breakdown of academic impact, for papers by Michael Andreeff Breakdown of academic impact, for papers by Shaji Kumar Breakdown of academic impact, for papers by Angela Dispenzieri Breakdown of academic impact, for papers by Charles L. Sawyers Breakdown of academic impact, for papers by Brian Druker Breakdown of academic impact, for papers by Francis J. Giles
Rankless by CCL
2026